Bristol-Myers Squibb [BMY] vs Gilead Sciences [GILD] Detailed Stock Comparison
Bristol-Myers Squibb
NYSE
Loading...
Gilead Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Bristol-Myers Squibb wins in 9 metrics, Gilead Sciences wins in 10 metrics, with 0 ties. Gilead Sciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bristol-Myers Squibb | Gilead Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 17.73 | 22.21 | Bristol-Myers Squibb |
| Price-to-Book Ratio | 5.15 | 7.11 | Bristol-Myers Squibb |
| Debt-to-Equity Ratio | 291.55 | 127.34 | Gilead Sciences |
| PEG Ratio | -0.77 | 1.02 | Bristol-Myers Squibb |
| EV/EBITDA | 6.66 | 11.49 | Bristol-Myers Squibb |
| Profit Margin (TTM) | 10.58% | 21.87% | Gilead Sciences |
| Operating Margin (TTM) | 33.68% | 39.16% | Gilead Sciences |
| EBITDA Margin (TTM) | 33.68% | 39.16% | Gilead Sciences |
| Return on Equity | 29.32% | 33.40% | Gilead Sciences |
| Return on Assets (TTM) | 8.33% | 12.62% | Gilead Sciences |
| Free Cash Flow (TTM) | $13.94B | $10.31B | Bristol-Myers Squibb |
| Dividend Yield | N/A | 3.25% | N/A |
| 1-Year Return | -15.25% | 30.70% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 1.88 | 4.84 | Bristol-Myers Squibb |
| Enterprise Value | $127.30B | $158.54B | Gilead Sciences |
| EV/Revenue Ratio | 2.67 | 5.49 | Bristol-Myers Squibb |
| Gross Profit Margin (TTM) | 72.52% | 78.80% | Gilead Sciences |
| Revenue per Share (TTM) | $23 | $23 | Bristol-Myers Squibb |
| Earnings per Share (Diluted) | $2.49 | $5.07 | Gilead Sciences |
| Beta (Stock Volatility) | 0.36 | 0.38 | Bristol-Myers Squibb |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Bristol-Myers Squibb vs Gilead Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | -3.58% | 5.34% | -3.54% | -3.99% | -23.27% | -19.48% |
| Gilead Sciences | -0.53% | -0.39% | -1.91% | -0.85% | -1.19% | 20.33% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | -15.25% | -34.39% | -26.03% | -25.57% | 68.37% | 98.83% |
| Gilead Sciences | 30.70% | 71.97% | 73.18% | 9.85% | 508.48% | 830.64% |
News Based Sentiment: Bristol-Myers Squibb vs Gilead Sciences
Bristol-Myers Squibb
News based Sentiment: POSITIVE
October was a notably positive month for Bristol Myers Squibb, driven by a strong earnings report, a strategic AI partnership, and proactive measures to address drug pricing. These developments, coupled with analyst upgrades and positive insider activity, suggest a strengthening investment case and improved future prospects.
Gilead Sciences
News based Sentiment: MIXED
October was a largely positive month for Gilead, with strong earnings and analyst upgrades offset by potential drug pricing pressures. The company's significant investments in R&D and manufacturing signal a commitment to long-term growth, but the Biktarvy pricing issue introduces a notable risk factor, creating a mixed overall investment narrative.
Performance & Financial Health Analysis: Bristol-Myers Squibb vs Gilead Sciences
| Metric | BMY | GILD |
|---|---|---|
| Market Information | ||
| Market Cap | $89.86B | $139.74B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 17,506,340 | 7,201,150 |
| 90 Day Avg. Volume | 12,232,973 | 6,413,223 |
| Last Close | $45.73 | $110.56 |
| 52 Week Range | $42.96 - $63.33 | $83.10 - $121.83 |
| % from 52W High | -27.79% | -9.25% |
| All-Time High | $81.44 (Nov 28, 2022) | $123.37 (Jun 22, 2015) |
| % from All-Time High | -43.85% | -10.38% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.01% | 0.02% |
| Quarterly Earnings Growth | -0.22% | 0.21% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.22% |
| Operating Margin (TTM) | 0.34% | 0.39% |
| Return on Equity (TTM) | 0.29% | 0.33% |
| Debt to Equity (MRQ) | 291.55 | 127.34 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $8.57 | $15.84 |
| Cash per Share (MRQ) | $6.68 | $4.88 |
| Operating Cash Flow (TTM) | $15.90B | $9.87B |
| Levered Free Cash Flow (TTM) | $16.19B | $8.84B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 3.25% |
| Last 12-Month Dividend | N/A | $3.91 |
Valuation & Enterprise Metrics Analysis: Bristol-Myers Squibb vs Gilead Sciences
| Metric | BMY | GILD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 17.73 | 22.21 |
| Forward P/E | 6.28 | 15.16 |
| PEG Ratio | -0.77 | 1.02 |
| Price to Sales (TTM) | 1.88 | 4.84 |
| Price to Book (MRQ) | 5.15 | 7.11 |
| Market Capitalization | ||
| Market Capitalization | $89.86B | $139.74B |
| Enterprise Value | $127.30B | $158.54B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.67 | 5.49 |
| Enterprise to EBITDA | 6.66 | 11.49 |
| Risk & Other Metrics | ||
| Beta | 0.36 | 0.38 |
| Book Value per Share (MRQ) | $8.57 | $15.84 |
Financial Statements Comparison: Bristol-Myers Squibb vs Gilead Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BMY | GILD |
|---|---|---|
| Revenue/Sales | $12.27B | $6.67B |
| Cost of Goods Sold | $3.37B | $1.54B |
| Gross Profit | $8.90B | $5.13B |
| Research & Development | $2.58B | $1.38B |
| Operating Income (EBIT) | $3.77B | $2.49B |
| EBITDA | $5.26B | $3.28B |
| Pre-Tax Income | $1.77B | $1.65B |
| Income Tax | $460.00M | $334.00M |
| Net Income (Profit) | $1.31B | $1.32B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BMY | GILD |
|---|---|---|
| Cash & Equivalents | $10.88B | $7.93B |
| Total Current Assets | $30.78B | $16.90B |
| Total Current Liabilities | $24.07B | $12.34B |
| Long-Term Debt | $47.51B | $22.15B |
| Total Shareholders Equity | $17.45B | $19.08B |
| Retained Earnings | $16.11B | $10.93B |
| Property, Plant & Equipment | $1.22B | $7.96B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BMY | GILD |
|---|---|---|
| Operating Cash Flow | $2.11B | $1.56B |
| Capital Expenditures | N/A | $-104.00M |
| Free Cash Flow | $1.69B | $1.65B |
| Debt Repayment | N/A | $-1.76B |
| Common Stock Repurchase | N/A | $-730.00M |
Short Interest & Institutional Ownership Analysis
| Metric | BMY | GILD |
|---|---|---|
| Shares Short | 29.47M | 18.25M |
| Short Ratio | 3.05 | 2.97 |
| Short % of Float | 0.01% | 0.01% |
| Average Daily Volume (10 Day) | 17,506,340 | 7,201,150 |
| Average Daily Volume (90 Day) | 12,232,973 | 6,413,223 |
| Shares Outstanding | 2.03B | 1.25B |
| Float Shares | 2.03B | 1.24B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.83% | 0.91% |
Dividend Analysis & Yield Comparison: Bristol-Myers Squibb vs Gilead Sciences
| Metric | BMY | GILD |
|---|---|---|
| Last 12-Month Dividend | N/A | $3.91 |
| Last 12-Month Dividend Yield | N/A | 3.25% |
| 3-Year Avg Annual Dividend | N/A | $3.30 |
| 3-Year Avg Dividend Yield | N/A | 0.91% |
| 3-Year Total Dividends | N/A | $9.91 |
| Ex-Dividend Date | N/A | Sep 15, 2025 |